Group sales In the first nine months of 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 45.9 billion due to strong demand for our pharmaceutical and diagnostic products.
BrightCraft’s updated structure integrates implantology, prosthodontics, orthodontics, cosmetic dentistry, and endodontics—all within one facility. This comprehensive, sedation-enabled environment ...
CEO Cannabix Technologies Inc. For further information, contact the Company at [email protected] The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of ...
Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces preclinical data for HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held ...
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one ...
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, ...
The full list of 2025 Expert Choice Award winners is available at HearAdvisor.com/awards. Founded in 2022, HearAdvisor provides objective, science-based evaluations of hearing technology. HearAdvisor ...
Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion ...
About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable ...
WILMINGTON, Del., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, ...
Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025.
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), today announced positive results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback